Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Apelin-13 cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established Apelin-13 cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Apelin-13 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Apelin-13 cycle length?
No. We found no human studies that report a treatment duration for Apelin-13.
What is the longest human study of Apelin-13?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Apelin-13 dosing reference Full research page

References

  1. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure Circulation. 2010
  2. Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp Diabetes Obes Metab. 2018
  3. Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers (APELINS-2, NCT02724566) ClinicalTrials.gov. 2026
  4. Apelin-13 ameliorates hypoxic-ischemic brain damage and improves neurological function in neonatal rats by attenuating neuroinflammation via AMPK activation Int Immunopharmacol. 2026
  5. Microneedle patch-based delivery of Pyr-Apelin-13 reverses functional and structural deficits in age-related sarcopenia Sci Rep. 2026
  6. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor Biochem Biophys Res Commun. 1998
  7. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist Hypertension. 2015
  8. Apelin-13 attenuates doxorubicin-induced myocardial injury via the PI3K/AKT and ERK/MAPK signaling pathways Cardiovasc Diagn Ther. 2026
  9. Apelin-13 Pretreatment Attenuates Age-Associated Renal Fibrotic Remodeling Following I/R Injury Biomedicines. 2026
  10. Apelin-13 drives VSMC proliferation and atherosclerosis through REEP5-dependent disruption of ER-mitochondria coupling and glycolytic shift Life Sci. 2026
  11. Retraction notice to "Apelin-13 impedes foam cell formation by activating Class III PI3K/Beclin-1-mediated autophagic pathway" Biochem Biophys Res Commun. 2026
  12. Apelin-13 (CID 25078060) PubChem. 2026
  13. Drugs@FDA application data queried through openFDA for apelin (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
  14. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026); no entry for apelin in any of the three categories FDA. 2026
  15. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026